EcoDrugPlus

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSPANG00000021090
Gene Symbol: PSMC1
5 Cross references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSPANG00000021273
Gene Symbol: PSMC2
5 Cross references
219 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSPANG00000017381
Gene Symbol: PSMC3
5 Cross references
214 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSPANG00000017750
Gene Symbol: PSMC4
5 Cross references
197 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 26s Subunit, Atpase 5

Ensembl ID : ENSPANG00000020980
Gene Symbol: PSMC5
5 Cross references
222 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 26s Subunit, Atpase 6

Ensembl ID : ENSPANG00000023304
Gene Symbol: PSMC6
3 Cross references
218 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSPANG00000004701
Gene Symbol: PSMD1
5 Cross references
210 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 26s Subunit, Non-Atpase 11

Ensembl ID : ENSPANG00000023029
Gene Symbol: PSMD11
5 Cross references
285 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 26s Subunit, Non-Atpase 12

Ensembl ID : ENSPANG00000020562
Gene Symbol: PSMD12
4 Cross references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 26s Subunit, Non-Atpase 13

Ensembl ID : ENSPANG00000014283
Gene Symbol: PSMD13
5 Cross references
220 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 26s Subunit, Non-Atpase 3

Ensembl ID : ENSPANG00000021749
Gene Symbol: PSMD3
5 Cross references
212 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 26s Subunit, Non-Atpase 6

Ensembl ID : ENSPANG00000014295
Gene Symbol: PSMD6
5 Cross references
212 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).